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Isoniazid (INH) remains a cornerstone key constitute of the current tuberculosis
management strategy, but its hepatotoxic potentiality remains a significant clinical
problem. Our previous findings succeed to establish a rat model of INH hepatotoxicity
employing the inflammatory stress theory in which non-injurious doses of inflammatory-
mediating agent bacterial lipopolysaccharides (LPS) augmented the toxicity of INH that
assist to uncover the mechanisms behind INH hepatotoxicity. Following LPS exposure,
several inflammatory cells are activated and it is likely that the consequences of this
activation rather than direct hepatocellular effects of LPS underlie the ability of LPS to
augment toxic responses. In this study, we investigated the potential protective role of
the anti-inflammatory agent dexamethasone (DEX), a potent synthetic glucocorticoid,
in INH/LPS hepatotoxic rat model. DEX pre-treatment successfully eliminates the
components of the inflammatory stress as shown through analysis of blood biochemistry
and liver histopathology. DEX potentiated hepatic anti-oxidant mechanisms while serum
and hepatic lipid profiles were reduced. However, DEX administration was not able to
revoke the principal effects of cytochrome P450 2E1 (CYP2E1) in INH/LPS-induced
liver damage. In conclusion, this study illustrated the DEX-preventive capabilities on
INH/LPS-induced hepatotoxicity model through DEX-induced potent anti-inflammatory
activity whereas the partial toxicity seen in the model could be attributed to the
expression of hepatic CYP2E1. These findings potentiate the clinical applications of
DEX co-administration with INH therapy in order to reduce the potential incidences of
hepatotoxicity.
Keywords: isoniazid, lipopolysaccharide, hepatotoxicity, dexamethasone, CYP2E1, inflammatory stress, oxidative
stress
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INTRODUCTION
Although isoniazid (INH) is a key component of the current
tuberculosis management strategy, but its hepatotoxic
potentiality remains a significant clinical problem (Yew
and Leung, 2006; Metushi et al., 2011). Despite extensive research
efforts for understanding the reasons behind INH-induced
liver toxicity, the exact underlying mechanisms are poorly
comprehended (Wang et al., 2016). As a part of the persistent
efforts to uncover the INH hepatotoxic mechanisms, our
previous work succeeds to establish a 2-week INH-induced
hepatotoxicity model (Hassan et al., 2016). In that model,
bacterial lipopolysaccharide (LPS), a Gram-negative bacterial
outer cell wall’s membrane constituent, clearly augmented
the INH-induced liver injury. The major theory behind this
enhancement activity was inflammatory stress theory, in which
an inflammatory-mediating agent caused an incidence of
systemic inflammation that might reduce xenobiotic toxicity
threshold therefore, intensify drug-induced toxicity (Yee et al.,
2000; Buchweitz et al., 2002; Deng et al., 2009). Moreover, most
of patients clinically suffering from INH-induced hepatotoxicity
show liver biopsy findings including necrosis and inflammation
which is mostly associated with eosinophils infiltration
(Bjornsson et al., 2007). Episodes of modest inflammation,
although benign on their own, are probably commonplace in
people and have the ability to augment the toxicities of several
xenobiotic agents (Liu et al., 2000; Lu et al., 2011). Indeed, it
has been suggested that exposure to endogenous LPS due to
increased movement of bacteria across a compromised intestinal
mucosa contributes to the hepatotoxicity produced by various
agent (Brown et al., 1996; Barton et al., 2000; Yee et al., 2000).
Moreover, LPS influences the pharmacokinetics of drugs (Ma
et al., 2011) by modulating the activities of both phase I (Pan
et al., 2003; Xu et al., 2006) and phase II (Richardson et al., 2006;
Alkharfy et al., 2008) drug-metabolizing enzymes. LPS influence
INH-induced hepatotoxicity by affecting INH pharmacokinetics
through LPS ability to suppress the protein translation and
mRNA transcription of cytochrome P450 isozymes, including
cytochrome P450 2E1 (CYP2E1; Hasegawa et al., 1999).
Co-administration of INH and LPS caused serious liver injury
and mixed hepatotoxicity in rats, including hepatocellular injury
and cholestasis (Su et al., 2014), which augments the role of
inflammation in INH-induced hepatotoxicity. These results raise
the possibility that a mild episode of inflammation might render
human patients susceptible to INH-induced liver injury.
Furthermore, the key role played by the over-production
of both CYP2E1 and reactive oxygen species (ROS) have also
been noticed, in which liver susceptibility toward inflammatory
mediators toxicity is elevated due to CYP2E1 over-expression. In
addition to increased liver ROS production, both LPS and INH
amplifies CYP2E1 production, which in returns exaggerates their
tissue damage capabilities (Lu and Cederbaum, 2010; Aubert
et al., 2011; Cederbaum et al., 2012).
For more than half a century, corticosteroids including
dexamethasone (DEX), a synthetic glucocorticoid, have been
used as a potent anti-inflammatory and immunosuppressive
agents in treatment of different inflammatory disorders
(Pang et al., 2012; Du et al., 2014). DEX also has anti-endotoxin
activity through intervening with pro-inflammatory mediators’
synthesis mechanisms (Yubero et al., 2012; Wang et al., 2013).
Therefore, our main goals in the present study are to alleviate the
augmenting effects of LPS in INH-mediated liver injury through
attenuation of the inflammatory stress by DEX administration
and to find out the possible mechanisms behind DEX protection
when co-administered with INH/LPS.
MATERIALS AND METHODS
Drugs and Reagents
INH (Lot number MKBV9475V, analytical standard ≥99%), LPS
(Lot number 025M4128V, derived from Escherichia coli 0128:B12
serotype, source strain is CDC 2440-69), were purchased from
Sigma-Aldrich (St. Louis, MO, USA). DEX as sodium phosphate
ready-made injections (Lot number 5160303) was obtained
from Hubei Chang Tian Pharmaceutical Company (Hubei,
China). TRIzol reagent bought from Invitrogen Life Technologies
(CA, USA) while PrimeScriptTM RT Master Mix from Takara
Biotechnology (Dalian, China) and SYBR Green Supermix from
Vazyme Biotech (Nanjing, China). Other reagents were from
high-analytical grade commercially available or as specified in the
relevant contexts.
Animals
Male, Sprague-Dawley rats weighing 200–220 g were obtained
from Shanghai Lingchang Biological Technology Co., Ltd.
(Shanghai, China). All experimental procedures were conducted
in accordance with the guide for Institutional Animal Care
and Use Committee at China Pharmaceutical University and
the National Institutes of Health (NIH) guidelines for the
care and use of laboratory animals. Rats were housed in
controlled environmental conditions (23± 1◦C, 55± 5% relative
humidity, 12 h light–dark cycle) with free access to food and
water ad libitum. Animals were acclimatized for 1 week before
conducting the experiments. All experimental procedures were
approved by China Pharmaceutical University, National Drug
Screening Centre and Jiangsu Institute of Materia Medica ethical
committees, Nanjing, China.
Experimental Design and Treatment
Schedule
Rats (n = 8 per group) were randomly divided into five groups:
control group (group I), INH 200 mg/kg (ig plus intravenous LPS
2 mg/kg (group II), INH 400 mg/kg (ig) plus intravenous LPS
2 mg/kg (group III), while both group IV and group V received
the same INH and LPS doses in addition to intraperitoneal DEX
(4 mg/kg).
INH was administered for 14 consecutive days, whereas LPS
was given as bolus dose at day 14, 2 h before the last INH
dose. DEX was also given as a single dose at day 14, 1 h
prior LPS administration. These selected concentrations were in
accordance with previous research on INH/LPS combinations
(Clayton et al., 2007; Metushi et al., 2012; Su et al., 2014; Hassan
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et al., 2016) and DEX (Dandona et al., 1999; Eum et al., 2003; Cui
et al., 2015). Rats were sacrificed after INH last dose; blood was
collected, allowed to clot at room temperature and centrifuged
for serum. Liver sections were isolated, frozen in liquid nitrogen
then stored for further experiments.
Serum and Liver Biochemistry
For hepatotoxicity determination, following the standard
enzymatic techniques, serum alanine transaminase (ALT),
aspartate transaminase (AST), total bile acids (TBA), total
bilirubin (TBil), gamma-glutamyl transferase (GGT), triglyceride
(TG), and total cholesterol (TC) levels were measured by
HITAC7170A automatic analyzer (Hitachi, Japan). Both liver
TG and TC were determined following the manufacturer’s
instructions of corresponding detection kits (Nanjing Jiancheng
Bioengineering Institute, Nanjing, China).
Histopathological Analysis
Immediately following sacrifice of the rats, histological
examinations were conducted on rat liver slices. Liver slices
were directly fixed in 10% paraformaldehyde solution and
embedded in paraffin wax, then stained with hematoxylin and
eosin (H&E). Slides were coded, randomized, and assessed by
pathologists who during the evaluation of the slides were blinded
to the treatment groups.
Oil Red O Staining
In order to verify accumulation of lipids in hepatic tissues
following INH/LPS co-treatment, fresh frozen liver sections were
treated with oil red O staining following the standard protocol
at Jiangsu Provincial Hospital of Integrated Traditional and
Western Medicine (Nanjing, China).
Determination of Hepatic Anti-oxidant
Levels
The levels of total superoxide dismutase (SOD), reduced
glutathione (GSH), malondialdehyde (MDA), and hepatic
total-anti-oxidant capacity (T-AOC) contents were detected
with their corresponding assay kits provided by Nanjing
Jiancheng Bioengineering Institute (Nanjing, China), according
to manufacturer instructions.
RNA Isolation and Quantitative
Real-Time Polymerase Chain Reaction
Total RNA was extracted from rat’s liver tissues by TRIzol
reagent (Invitrogen Life Technologies, Carlsbad, CA, USA)
following manufacturer instructions provided, 1 µg RNA was
quantified using 2000 Nanodrop Spectrophotometer (Thermo
Fisher Scientific, Wilmington, DE, USA) then reverse-transcribed
into cDNA with PrimeScriptTM RT Master Mix (Takara
Biotechnology, Dalian, China). Quantitative polymerase chain
reaction (PCR) was executed in 20 µL volume containing 10 µL
SYBR Green Supermix (Vazyme Biotech, Nanjing, China), 1 µL
of cDNA, 7 µL of RNase/DNase-free water and 500 nM each
primer. The thermal cycler conditions were as follows: 30 s at
95◦C, followed by 40 cycles of 5 s at 95◦C and 10 s at 60◦C.
A melting curve analysis was carried out for each reaction from
65 to 95◦C. The threshold cycle at which the fluorescent signal
reached an arbitrarily set threshold near the middle of the log-
linear phase of amplification for each reaction was calculated, and
relative quantities of each mRNA were determined. Primers used
for PCR were listed in Supplementary Table S1. Gene expression
was evaluated by 11CT method in which glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) served as a reference gene.
Western Blot Analysis
Protein samples were extracted from liver tissues with
radioimmunoprecipitation assay (RIPA) buffer with phosphatase
and protease inhibitors (Beyotime, China). The extracted
proteins (70 µg) were quantified by bicinchoninic acid protein
assay kit (Beyotime, China) and prepared with 4× sample buffer
(BD Biosciences, USA). Following their separation in sodium
dodecyl sulfate polyacrylamide gel electrophoresis, proteins
were transferred to the polyvinylidene difluoride membranes,
blocked with 5% bovine serum albumin (BSA) for 1 h and
further incubated with specific primary antibodies overnight.
The proteins in bands were then incubated with secondary
antibodies and detected on a Bio-Rad Gel Doc XR+ Imaging
System (CA, USA). Primary and secondary antibodies used
for western blotting were listed in Supplementary Tables S2,S3,
respectively.
Terminal Deoxynucleotidyl TUNEL
Staining and Immunohistochemistry
Paraffin-embedded liver sections were stained by transferase
dUTP nick-end labeling (TUNEL) assay in order to identify
apoptotic hepatocytes using TUNEL detection kit (KeyGEN
BioTECH, Nanjing, China) following the manufacturer’s
guidelines. TUNEL-stained liver samples were captured with
light microscope (Olympus IX81). Immunohistochemistry
testing was performed for CYP2E1 and peroxisome proliferator-
activated receptors alpha (PPARα) using corresponding
antibodies on hepatic tissues fixed in formaldehyde and
embedded in 3 µ paraffin slices.
Statistical Analysis
The data in all experiments are expressed as mean ± SD.
Statistical comparisons were performed by one-way analysis
of variance; difference between two groups was analyzed by
Student’s two-tailed t-test using GraphPad Prism 6.0 (Graph-Pad,
San Diego, CA, USA). The level of significance was set at P-value
<0.05.
RESULTS
LPS Aggravated INH Hepatotoxicity
While DEX Alleviated LPS-Induced
Toxicity Augmentation
INH/LPS co-treated animals showed reduction in both total
body weight and liver weight, while DEX-pretreated rats
revealed insignificant partial increment in total body weight with
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FIGURE 1 | Effects of DEX administration on liver injury parameters induced by INH/LPS co-administration. Rats were treated with INH 200 or 400 mg/kg
for 14 consecutive days, at day 14 they were given 4 mg/kg DEX 1 h earlier before they received 2 mg/kg LPS dose followed by INH 2 h later. (A) Effects on body
weight. (B) Liver weight variation. (C) Impact on serum TBA and TBil levels. (D) Alterations in serum ALT, AST, and GGT levels. Data were represented as
mean ± SD, n = 8 for each bar. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus control, #P < 0.05, ##P < 0.01, ###P < 0.001 versus INH/LPS combination.
improvement in liver weight nearly up to the control group
ones (Figures 1A,B). Meanwhile, serum markers of liver injury
including TBA, TBil, and GGT showed significant elevation
in the animal groups treated by INH and LPS combination,
with highest increase within INH dose 400 mg/kg. Pre-addition
of DEX reduced serum TBil and GGT levels to those in the
control group (i.e., significantly indifferent from control group
measurement) while TBA level remained elevated, especially in
the rat group that received INH 400 mg/kg (Figures 1C,D).
In line with our previous results, serum ALT level showed
significant reduction in INH/LPS-treated rats, while those
receiving DEX revealed marginal increment but still beneath the
control levels. Furthermore, AST levels insignificantly fluctuated
in the INH/LPS co-treated rats, while administration of DEX
resulted in normal control levels (Figure 1D). Histopathological
evaluation revealed massive hepatocellular damage, necrosis,
micro-and macro-vesicular steatosis accompanied with severe
inflammation and inflammatory infiltration in INH/LPS-treated
rats (Figure 2A). However, in DEX-administered rats there
were no signs of inflammation, inflammatory infiltration, or
steatosis rather than minor hepatocellular necrosis as observed
and indicated in the histological toxicity score (Figure 2B).
Hepatic Fat is Reduced in
INH/LPS-Treated Rats Following DEX
Administration
Since micro- and macro-vesicular lipid droplets had been
obviously accumulated and easily detected under microscope
after H&E staining, we carried out oil red O staining. As shown
in Figure 3A, both 200 and 400 mg/kg INH plus LPS groups
displayed intense dose-dependent micro- and macro-vesicular
steatosis as confirmed by the strong staining, while liver slides
from DEX pre-treated rats showed minor staining of lipid
droplets, indicating that DEX minimizes the steatotic-induction
abilities of INH/LPS co-treatment.
To validate the changes in hepatic lipid profile, both
hepatic TG and TC were quantified using their corresponding
quantification kits. Hepatic TC level was significantly increased
in INH/LPS-treated animals, with high elevation observed in
rats receiving INH 400 mg/kg (Figure 3B). Meanwhile, hepatic
TG level also showed significant elevation in rats administered
INH/LPS combination, but in rats pre-treated with DEX, their
liver TG levels rendered almost to the normal control levels.
Moreover, serum TC and TG levels were significantly elevated
after administration of INH/LPS combination, while serum TG
level significantly reduced in rats given DEX whereas serum TC
levels were kept raising (Figure 3B).
Hepatic Oxidative Stress-Related
Parameters
Oxidative stress created from the imbalance between free radicals’
generation and removal following INH treatment has being
proposed to be one of the causative mechanisms by which INH
could produce hepatic damage (Shen et al., 2007; Rao et al.,
2012). As indicated in Figure 4, INH/LPS combination showed
a significant reduction in both SOD and T-AOC levels with
maximum reduction observed at animal group receiving INH
400 mg/kg, which were significantly improved after addition
of DEX. Furthermore, MDA is one of the oxidative stress
factors being produced as a result from lipid peroxidation, MDA
determination showed significant elevation in INH/LPS-treated
rats with highest elevation observed in INH dose 400 mg/kg,
while DEX pre-administered groups, their MDA levels returned
to the normal control ones.
Liver GSH levels exhibited significant inhibition especially in
INH 400 mg/kg plus LPS. Meanwhile, rats pre-treated with DEX
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FIGURE 2 | DEX protects against INH/LPS-induced hepatic damage as indicated by liver histopathological examination. (A) Liver slices were collected
and subjected to staining with hematoxylin and eosin. Control group showed normal hepatocyte architecture, meanwhile INH/LPS co-treated animals liver showed
sever toxicity symptoms. Inflammatory cells and inflammatory infiltration (green arrow), micro- and macrovesicular steatosis (white arrow), massive necrosis (black
arrow), and hepatocellular structure loss (red arrow). On the other hand, DEX pre-treatment minimized these liver injury indicators (B) INH/LPS hepatotoxicity score in
absence or presence of DEX. Data were represented as mean ± SD, n = 8 for each bar. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus control, #P < 0.05,
##P < 0.01, ###P < 0.001 versus INH/LPS combination.
FIGURE 3 | Lipid profile analysis. (A) Lipid staining in rat livers. Frozen liver sections were stained with red oil O staining; massive steatosis seen in rats received
INH/LPS co-treatment whereas DEX addition decreased hepatic lipid accumulation. (B) Variation in both serum and hepatic lipid profile. Data were represented as
mean ± SD, n = 8 for each bar. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus control, ##P < 0.01, ###P < 0.001 versus INH/LPS combination.
revealed improvement in GSH levels. These results indicated that,
hepatic anti-oxidant abilities have been raised due to the DEX
pretreatment which led to minimum hepatocellular damage and
reduced the liver injury.
Hepatic Gene Expressions in
INH/LPS-Induced Liver Injury
Due to the elevation of serum bile acids parameters mainly
TBA, TBil, and GGT in rats receiving INH/LPS combination,
we carried out further investigation of the relevant genes
associated with bile acids. As indicated in Figure 5A, both
farnesoid X receptor (FXR) and small heterodimer partner (SHP)
expressions were significantly repressed in INH/LPS-treated
groups, DEX pretreatment did not restore their corresponding
control levels but it clearly affected expressions of CYP7A1,
CYP27A1, and CYP8B1, the genes responsible for bile acid
synthesis, which were significantly over-expressed in animal
groups receiving DEX (Figure 5B). These genes significant
over-expressions were positively correlated with the observed
serum TBA elevation.
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FIGURE 4 | INH/LPS caused modifications in oxidative stress and hepatic anti-oxidant defense mechanisms while DEX pre-administration helped in
elevation of liver anti-oxidant defense. Changes in SOD, T-AOC, MDA, and GSH levels were measured by their relevant kits. Data were represented as
mean ± SD, n = 8 for each bar. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus control, #P < 0.05, ##P < 0.01, ###P < 0.001 versus INH/LPS combination.
FIGURE 5 | Effects of INH/LPS combination on different targeted genes and proteins profile in absence or presence of DEX. (A) Bile acid regulators FXR
and SHP expression. (B) Expression of bile acid synthesis enzymes CYP7A1, CYP27A1, and CYP8B1. (C) Bile acid transporters BSEP, NTCP, MRP2, and OATP1
expression. (D) Inflammatory mediators IL-6, TNFα, IL-1α, IL-1β, and INFγ expression. (E) Expression of CYP2E1. (F) Lipid profile regulators PPARα, FAS, and
HMGCS expression. Data were represented as mean ± SD, n = 8 for each bar. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus control, #P < 0.05, ##P < 0.01,
###P < 0.001 versus INH/LPS combination, GAPDH was set as reference control gene. (G) Immunoblotting analysis of different targeted proteins following INH/LPS
with or without DEX treatment, β-actin considered as loading control.
In the meantime, the repression of bile acid transporters
bile salt export pump (BSEP), Na+-taurocholate co-transporting
polypeptide (NTCP), organic anion-transporting polypeptide
1 (OATP1) and multi-drug resistance protein (MRP2) seen
following INH/LPS treatment also indicated the accumulated
levels of toxic bile acids in the hepatocytes. Surprisingly,
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DEX pretreatment significantly elevated BSEP and MRP2
expression indicated the reduction of the hepatocyte toxic bile
acids accumulation, but DEX showed no improving signs on
NTCP and OATP1 expressions (Figure 5C). Meanwhile, DEX
administration also caused MRP3 over-expression (data not
shown) which could further explained the elevated serum bile
acids level noticed in rats received both DEX and INH/LPS
combination.
Although immune system’s role have been neglected in the
pathogenesis of INH-induced liver toxicity due to the absence
of fever, rash, eosinophilia, and rapid start of INH toxicity
upon dose resuming (Metushi et al., 2016), but more recent
findings support the relationship between INH toxicity and
immune system (Salazar-Paramo et al., 1992; Metushi et al., 2011;
Metushi et al., 2014). Consistently with these recent findings, our
results demonstrated that, the inflammatory mediator cytokines
as interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), IL-
1α, IL-1β, and interferon gamma (INFγ) were significantly over-
expressed in INH/LPS-treated rats whereas DEX pre-treatment
significantly reversed their levels to their corresponding control
group values (Figure 5D) therefore, eliminating the augmented
role of the LPS through prevention of the inflammatory stress.
Many researchers, including our previous report, focused
on the core role played by CYP2E1 in INH toxicity (Yue
et al., 2004; Cheng et al., 2013; Shayakhmetova et al., 2015;
Hassan et al., 2016), we found a positive correlation between
INH hepatotoxicity and CYP2E1. Spectacularly, CYP2E1 at
its gene expression level almost dwindled in all INH/LPS-
treated rats, even those already receiving DEX (Figure 5E).
Meanwhile, hepatic lipid accumulation as evidenced by analysis
of hepatic TC and TG and red oil O staining led us to
study the change in the PPARα, which is highly expressed
in liver and accumulating evidences report the vital role of
PPARα in the regulation of hepatic lipid profile (Silva et al.,
2015). Figure 5F also displayed the significant repression of
PPARα in INH/LPS groups while in rats pre-treated with DEX;
their PPARα expression was significantly elevated. Furthermore,
the enzymes responsible for synthesis of lipids, mainly fatty
acid synthase (FAS) and hydroxymethylglutaryl-CoA synthase
(HMGCS) revealed significant reduction in INH/LPS groups,
which might be attributed to the severe accumulation of hepatic
lipids, while those receiving DEX their FAS and HMGCS
expression levels were nearly normal (Figure 5F).
Corresponding Protein Expressions
Analyzed by Both Western Blot and
Immunohistochemistry
Associated with their relevant expressed genes, protein levels of
FXR, SHP, and NTCP were reduced in INH/LPS-treated rats
whereas their expression levels were elevated in rats received
DEX, except for FXR (Figure 5G). Meanwhile, CYP7A1 protein
expression was reduced in the absence of DEX, while in the
presence of DEX, INH/LPS-treated animals showed supreme
protein level, which was clearly in match with its gene expression
level and further explained the elevated serum TBA observed in
these rats.
CYP2E1 protein level showed pronounced elevation in
animals receiving INH/LPS combination with highest increment
observed in rats received LPS/INH 400 mg/kg. Unexpectedly
DEX pre-treatment did not completely block CYP2E1 protein
expression, but only caused marginal reduction in CYP2E1
protein expression, fortifying the fact that, LPS only over-
activated and sensitize the liver toward CYP2E1 effects, therefore
blocking of LPS will not lead to CYP2E1 inhibition. Interestingly,
CYP2E1 immunohistochemistry results revealed that, in line
with the protein levels, INH/LPS-treated rats had more intense
coloration reflected the hepatocellular CYP2E1 accumulation.
In contrast, rats received DEX pre-treatment, their hepatocyte
CYP2E1 level was significantly reduced as indicated by more
fading colors (Figures 6A,B).
We also focused on the protein level of PPARα in liver
after INH/LPS treatment in order to verify the PCR result.
Western blot and immunohistochemistry experiments showed
that, PPARα protein expression was significantly down-regulated,
but its expression was up-regulated in the DEX pre-administered
groups (Figures 7A,B).
DEX Prevented Hepatocellular Apoptosis
in INH/LPS Model
As experimentally evident, most of INH liver damage came
through apoptotic induction in hepatocytes and breaks of
DNA strands (Lee et al., 2013; Perwitasari et al., 2015). As
displayed in Figure 8A after TUNEL assay application, no
observation of hepatocyte apoptosis in the control group,
whereas following INH/LPS co-treatment, rat hepatocytes were
stained TUNEL positive, however, addition of DEX led to a
decrease in this apoptotic activity, revealing that DEX suppressed
the apoptotic-stimulating effect of LPS on INH toxicity. This
finding was further fortified by analysis of the indicator of
cellular apoptosis, hepatic cleavage caspase-3 protein levels, in
which groups received INH/LPS co-therapy manifested higher
protein expression which was not present after DEX addition
(Figure 8B).
DISCUSSION
Despite its ability to generate liver toxicity, INH remains
an indispensable first-line drug for treatment of tuberculosis
especially latent tuberculosis, but the exact mechanisms by which
INH induces liver injury are not fully understood (Boelsterli and
Lee, 2014; Metushi et al., 2016). Our group early studies succeed
to establish a rat model of INH hepatotoxicity employing the
inflammatory stress theory in which non-injurious doses of an
inflammatory-mediating agent (LPS) augmented the toxicity of
INH (Su et al., 2014; Hassan et al., 2016). In order to confirm
our previous findings, we conducted the same preceding 14
days experiment with addition of DEX, a potent glucocorticoid
anti-inflammatory agent, to alleviate LPS potentiation activity
and to relieve the associated symptoms of INH hepatic injury,
which have been extensively reported to be indistinguishable
from hepatitis symptoms (Bjornsson et al., 2007).
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FIGURE 6 | Variations in hepatic CYP2E1 protein expression. (A) INH/LPS treatment elevated CYP2E1 expression, especially in rats received INH 400 mg/kg
(deep brown color). Moreover, DEX administration marginally reduced CYP2E1 expression probably through elimination of LPS-enhancing effects, as indicated by
the decreased color intensity. (B) CYP2E1 immunoblotting analysis, β-actin used as internal control.
FIGURE 7 | Alterations of PPARα expression in rat liver. (A) Photomicrograph of PPARα in rat liver immunohistochemistry, control group showed brown staining
(color indicating PPARα) while INH/LPS-treated rats their PPARα expression was significantly reduce as indicated by color fading. DEX pre-treatment ameliorate
PPARα expression after INH/LPS treatment. (B) Total liver protein was probed for PPARα, β-actin considered as loading control.
We again successfully established INH/LPS-induced liver
injury model as verified by body weight reduction, blood
biochemical parameters and histopathology, DEX pretreatment
assisted in restoration of INH/LPS-treated rat’s livers to their
corresponding normal control as evidenced by reduced serum
levels of TBil, GGT as well as histological examination. Due to
the fact that serum ALT and AST levels, which are considered
as the cornerstone indicators of liver damage, were unreliable
in judging INH-induced liver injury because of their time-
dependent variations (Karthikeyan, 2004; Metushi et al., 2012;
Jahan et al., 2015), serum TBA, TBil, and GGT levels might
be perfect substitutes as marker diagnostic parameters for
INH hepatotoxicity. Based on this assumption, DEX helped in
prevention of INH-induced liver damage as indicated by TBil
and GGT reduction. However, our results revealed that DEX-
pretreated rats, especially those received INH 400 mg/kg, their
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FIGURE 8 | INH/LPS treatment caused apoptosis in hepatic tissues, meanwhile DEX prevented hepatocellular apoptosis in INH/LPS. (A) TUNEL assay
was conducted on liver slices; INH/LPS co-administration caused obvious positive TUNEL results (intensity of brown color indicating apoptotic action). In the
meantime, DEX restrained INH/LPS tendency to induce apoptosis (absence of brown color). (B) Representative western blot analysis of cleaved caspase-3 (β-actin
used as internal control).
FIGURE 9 | Schematic presentation highlighting the proposed mechanisms by which INH/LPS-induced hepatotoxicity and the DEX mechanistic
intervention for liver protection in INH/LPS liver injury model.
serum TBA levels were significantly elevated. This elevation was
coherent with the up-regulation of the bile acid synthesizing
genes CYP8B1, CYP7A1, and CYP27A1. Interestingly, these
bile acid synthesizing genes showed the same repressive effects
as previously observed in the animals administered INH/LPS
combination (Hassan et al., 2016), mimicking their feedback
inhibition theory due to accumulation of extreme hepatocellular
bile acids levels (Kunne et al., 2014).
Frontiers in Pharmacology | www.frontiersin.org 9 March 2017 | Volume 8 | Article 133
fphar-08-00133 March 13, 2017 Time: 16:44 # 10
Hassan et al. Dexamethasone Prevents INH/LPS-Induced Hepatotoxicity
As being considered the cornerstone rate-limiting enzyme
in the synthesis of bile acids from catabolism of cholesterol,
CYP7A1 expression regulates the bile acids level (Fan et al.,
2015) while CYP27A1 acts as the alternative pathway in the
bile acids production (Zhou and Hylemon, 2014). Furthermore,
DEX-induced BSEP over-expression could also participates
as a secondary cause for serum bile acid elevations seen
in DEX-treated animals. Glucocorticoids, including DEX, are
known to increase bile acid production (Lu et al., 2012) through
augmentation of synthesizing enzymes CYP7A1 and CYP27A1
(Princen et al., 1989; Liu et al., 2008) and elevate expressions
for both BSEP and MRP3 (Mörk et al., 2016) that enhance
bile acid secretion which end up in serum accumulation of
bile acids. Moreover, endotoxin mainly down-regulates MRP2
expression both at mRNA and protein levels (Kubitz et al., 1999)
therefore, DEX-induced MRP2 up-regulation could be attributed
to its anti-endotoxin activity which counteracts the LPS-induced
MRP2 repression. Although glucocorticoids treatment is usually
associated with NTCP up-regulation (Xiao et al., 2016), DEX
pre-administration only succeed in elevation of the NTCP
protein expression while no effect was observed on mRNA gene
expression level.
Accretion of toxic bile acid levels in the hepatocytes could
induce oxidative stress that promotes liver damage (Nomoto
et al., 2009). Moreover, inflammation, either induced by toxic
bile acids (Allen et al., 2011), INH (Chen et al., 2011, 2013) or
LPS administration (Sekine et al., 2010) and hepatic CYP2E1
(Warren et al., 1999), further potentiates the hepatocyte oxidative
stress which was very obvious in our results through elevation
of MDA level and the reduction of GSH, SOD, and T-AOC
levels. However, pre-addition of DEX assisted in improving
the hepatic anti-oxidant mechanisms mainly via inhibition of
LPS-induced intracellular ROS production (Huo et al., 2011).
On the other hand, INH/LPS combination obviously provoked
liver damage, necrosis, and hepatocellular apoptosis as indicated
by histopathological evaluation, elevated cleavage caspase-3 level
and TUNEL assay whereas combining DEX with INH/LPS help
protects from liver injury. One assumption of this protection
is DEX strengthening of hepatic anti-oxidant mechanisms that
prevent hepatocyte oxidative stress-induced damage, also its
ability to protect hepatocytes from toxic bile acids accumulation.
Moreover, DEX is believed to prevent both necrosis and
apoptosis, not only in liver but also in other tissues such as
the kidney, through inhibition of caspase-3 activity and up-
regulation of anti-apoptotic protein Bcl-xL (Moller et al., 2015).
Therefore, inhibition of caspase-3 activity and induction of Bcl-
xL not only prevent tissue necrotic and apoptotic potentials,
but also exerts a potent anti-inflammatory response that help in
suppressing immune-system mediated liver damage (Malhi et al.,
2006).
Furthermore, DEX down-regulates the inflammatory
mediators such as IL-6, TNF-α, IL-1α, IL-1β, and INFγ which
were over-expressed in INH/LPS-treated rats and potentiate
the INH/LPS apoptotic-inducing capabilities. This potent anti-
inflammatory effect could be responsible for DEX-mediated
liver protection as many recent studies are in agreement with
this concept (Hsieh et al., 2004, 2006; Yubero et al., 2009).
This DEX protection is not only limited to the liver tissues,
but also brain tissues (Pang et al., 2012; Du et al., 2014) and
inflammatory-induced microcirculation dysfunction (Cui et al.,
2015). Surprisingly, Yubero et al. (2012) concluded that DEX
although achieved a potent inflammatory cytokines inhibition,
but it failed to protect the lung tissue injury.
Alongside it is central key role in ROS generation, CYP2E1
play an essential role in INH/LPS-induced hepatotoxicity. INH
and its metabolites are responsible for hepatic CYP2E1 induction
(Yue et al., 2004; Cheng et al., 2013). Meanwhile, LPS and
CYP2E1 shared a unique relationship in which bacterial LPS
not only stimulating CYP2E1 expression, but also increases
the hepatic sensitivity toward CYP2E1 that further exaggerates
INH/LPS toxicity (Lu and Cederbaum, 2010; Cederbaum et al.,
2012; Shayakhmetova et al., 2015). Our results clearly indicated
that DEX assisted in marginal reduction of CYP2E1 expression,
but its capability to fully block CYP2E1 was unsuccessful. This
marginal reduction could be ascribed to DEX-mediating LPS
inhibition. Moreover, CYP2E1 has the tendency to heighten
the bile acid level through an efficacious role in bile acid
synthesis pathway (Cheng et al., 2013), which further explained
the elevated serum TBA level spotted in DEX pre-treated
animals. Previous studies extensively reported that CYP2E1
expression is totally not affected by DEX (Monostory and
Vereczkey, 1994; Burkina et al., 2013), however, in contradiction
to these studies, others documented the DEX-induced CYP2E1
expression potential (Sampol et al., 1997; Zerilli et al., 1998;
Tamasi et al., 2001). Regardless these controversial findings about
DEX effect on CYP2E1 expression, our experimental outcomes
distinctly abolish the hypothesis that DEX could entirely block
CYP2E1 expression. Our experiments indicate that partial liver
injury seen in rat groups received INH/LPS combined with DEX
might be due to the CYP2E1-inhibition inabilities of DEX.
Researchers are very familiar with the potential activities of
PPARα in liver and other extremely metabolic-active tissues,
those activities extend between adipocyte differentiation, fatty
acid oxidation, inflammation as well as glucose and lipid
metabolism (Corton et al., 2014). On the other hand, PPARα
and its agonist positively adjust the expression of the key
regulator genes involved in hepatic lipogenesis such as FAS and
HMGCS (Kunne et al., 2014; Pawlak et al., 2015). Furthermore,
PPARα has a participatory part in hepatic preservation from
inflammation (Stienstra et al., 2007), oxidative stress through
CYP2E1 up-regulation (Okiyama et al., 2009), hepatic fat
accumulation and hepatocellular apoptosis (Abdelmegeed et al.,
2011). Our established INH/LPS hepatotoxicity rat model
revealed repression of PPARα at both mRNA and protein levels
which were accompanied by elevated serum and hepatic TC
and TG levels as well as micro- and macro-vesicular lipid
vacuoles as shown in the liver histopathology and oil red O
staining. In contrast, DEX pre-treated rats showed elevated levels
of PPARα, that reflected reduction of hepatic inflammation,
increased hepatic anti-oxidant activity and liver steatosis.
Our comprehensive examinations of DEX-administration to
INH/LPS-treated rats can be entirely interpreted in Figure 9.
In conclusion, this study elucidated the DEX-preventive
capabilities on INH/LPS-induced hepatotoxicity model. These
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data strengthened the fact that bacterial inflammation as well
as CYP2E1 over-expression initiate and propagate INH-induced
liver injury while potent anti-inflammatory agents such as DEX
could strongly prevent the inflammatory stress. These findings
potentiate the clinical applications of DEX co-administration
with INH therapy in order to reduce the potential incidences
of hepatotoxicity. Although DEX significantly alleviates both
inflammatory and oxidative stress, but it showed no major effect
on the hepatic CYP2E1 expression. Therefore, additional studies
using specific CYP2E1 inhibitors or other techniques are needed
to further explain CYP2E1 participation in INH-induced liver
damage.
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